KR20130119928A - 피리미딘 유도체의 제조 방법 - Google Patents

피리미딘 유도체의 제조 방법 Download PDF

Info

Publication number
KR20130119928A
KR20130119928A KR1020137011172A KR20137011172A KR20130119928A KR 20130119928 A KR20130119928 A KR 20130119928A KR 1020137011172 A KR1020137011172 A KR 1020137011172A KR 20137011172 A KR20137011172 A KR 20137011172A KR 20130119928 A KR20130119928 A KR 20130119928A
Authority
KR
South Korea
Prior art keywords
substituted
formula
compound
unsubstituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137011172A
Other languages
English (en)
Korean (ko)
Inventor
존 빈센트 칼리에니
마릴린 데 라 크루즈
디트마 플루바하
바오칭 공
프라사드 코테스와라 카파
피오트르 에이치. 카르핀스키
후이 리우
파스칼 미셀
라스무스 모스
마리아 카트리나 테스타
릴라드하르 멀리드하르 웨이콜
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44773179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130119928(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20130119928A publication Critical patent/KR20130119928A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
KR1020137011172A 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법 Ceased KR20130119928A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38872110P 2010-10-01 2010-10-01
US61/388,721 2010-10-01
US201161494915P 2011-06-09 2011-06-09
US61/494,915 2011-06-09
PCT/US2011/053808 WO2012044727A2 (en) 2010-10-01 2011-09-29 Manufacturing process for pyrimidine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032263A Division KR20180123586A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법

Publications (1)

Publication Number Publication Date
KR20130119928A true KR20130119928A (ko) 2013-11-01

Family

ID=44773179

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137011172A Ceased KR20130119928A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법
KR1020187032263A Ceased KR20180123586A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187032263A Ceased KR20180123586A (ko) 2010-10-01 2011-09-29 피리미딘 유도체의 제조 방법

Country Status (30)

Country Link
US (3) US9181215B2 (enExample)
EP (2) EP2621908A2 (enExample)
JP (3) JP5998145B2 (enExample)
KR (2) KR20130119928A (enExample)
CN (3) CN104987321A (enExample)
AR (1) AR083213A1 (enExample)
AU (4) AU2011308856B2 (enExample)
BR (1) BR112013007123B1 (enExample)
CA (1) CA2813333C (enExample)
CL (2) CL2013000850A1 (enExample)
CO (1) CO6700837A2 (enExample)
DK (1) DK3040333T3 (enExample)
EC (1) ECSP13012596A (enExample)
ES (1) ES2699951T3 (enExample)
GT (1) GT201300080A (enExample)
HU (1) HUE041326T2 (enExample)
IL (3) IL225113A (enExample)
LT (1) LT3040333T (enExample)
MX (1) MX354482B (enExample)
MY (1) MY160785A (enExample)
NZ (1) NZ608285A (enExample)
PE (1) PE20140002A1 (enExample)
PH (2) PH12013500579A1 (enExample)
PL (1) PL3040333T3 (enExample)
PT (1) PT3040333T (enExample)
RU (2) RU2015150728A (enExample)
SG (1) SG188439A1 (enExample)
SI (1) SI3040333T1 (enExample)
TW (1) TWI540133B (enExample)
WO (1) WO2012044727A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140040770A (ko) 2011-07-01 2014-04-03 노파르티스 아게 암 치료에 사용하기 위한 cdk4/6 억제제 및 pi3k 억제제를 포함하는 조합 요법
PH12014500682A1 (en) 2011-09-27 2014-05-12 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
ES2605638T3 (es) * 2012-10-23 2017-03-15 Novartis Ag Proceso Mejorado para fabricar 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9318944B2 (en) 2013-04-29 2016-04-19 Rockwell Automation Technologies, Inc. Methods and apparatus for active front end filter capacitor degradation detection
US9294005B2 (en) 2013-10-01 2016-03-22 Rockwell Automation Technologies, Inc. Method and apparatus for detecting AFE filter capacitor degradation
RU2663999C2 (ru) * 2013-10-16 2018-08-14 Шанхай Инли Фармасьютикал Ко., Лтд Конденсированное гетероциклическое соединение, способ его получения, его фармацевтическая композиция и применения
RU2688665C2 (ru) * 2014-04-22 2019-05-22 Университет Базель Новый способ получения производных триазина, пиримидина и пиридина
CN105085476B (zh) * 2014-11-24 2018-03-09 苏州晶云药物科技有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
CN107001348B (zh) * 2014-12-17 2019-10-11 上海海雁医药科技有限公司 2-吗啉-4,6-二取代的嘧啶衍生物、其制法与医药上的用途
US9481665B2 (en) * 2015-03-13 2016-11-01 Yong Xu Process for preparing PI3K inhibitor buparsilib
EP3273959A1 (en) 2015-03-25 2018-01-31 Novartis Ag Pharmaceutical combinations
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
CN106543140A (zh) * 2015-09-21 2017-03-29 苏州晶云药物科技有限公司 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
PL3978500T3 (pl) * 2015-12-16 2024-03-11 Genentech, Inc. Sposób wytwarzania tricyklicznych związków inhibitorów pi3k
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN107793394A (zh) * 2017-08-03 2018-03-13 上海厚璞生物科技有限公司 一种生产选择性pi3k抑制剂的系列关键中间体
CN110016142B (zh) * 2019-04-30 2021-08-03 合肥工业大学 一种含嘧啶硼酸结构的硅油及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124476A (en) 1998-04-17 2000-09-26 Symyx Technologies, Inc. Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates
CN1735598A (zh) * 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
CA2507100C (en) 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2057140B1 (en) 2006-08-24 2012-08-08 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
MX2009008341A (es) * 2007-02-06 2009-08-12 Novartis Ag Inhibidores de cinasa de pi3 y metodos para su uso.
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
JP2012526772A (ja) * 2009-05-15 2012-11-01 ノバルティス アーゲー ホスホイノシチド３−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤

Also Published As

Publication number Publication date
HK1220686A1 (en) 2017-05-12
MY160785A (en) 2017-03-15
MX2013003507A (es) 2013-05-20
US20130225571A1 (en) 2013-08-29
US20160251334A1 (en) 2016-09-01
WO2012044727A2 (en) 2012-04-05
JP2013541536A (ja) 2013-11-14
US20150232446A1 (en) 2015-08-20
BR112013007123A2 (pt) 2016-06-14
KR20180123586A (ko) 2018-11-16
IL233282A0 (en) 2014-08-31
CA2813333A1 (en) 2012-04-05
PT3040333T (pt) 2018-12-04
IL225113A (en) 2016-08-31
CO6700837A2 (es) 2013-06-28
JP2016128414A (ja) 2016-07-14
CL2015001088A1 (es) 2015-07-10
ECSP13012596A (es) 2013-07-31
US9359326B2 (en) 2016-06-07
WO2012044727A3 (en) 2012-06-07
AU2011308856A1 (en) 2013-03-28
IL238046A (en) 2016-08-31
EP3040333A1 (en) 2016-07-06
CN103140479A (zh) 2013-06-05
AU2015246141A1 (en) 2015-11-12
NZ608285A (en) 2014-06-27
TW201215605A (en) 2012-04-16
GT201300080A (es) 2014-07-18
MX354482B (es) 2018-03-07
CA2813333C (en) 2019-01-15
RU2013120326A (ru) 2014-11-20
JP5998145B2 (ja) 2016-09-28
AR083213A1 (es) 2013-02-06
PH12015501585A1 (en) 2015-09-21
HUE041326T2 (hu) 2019-05-28
CN104945373A (zh) 2015-09-30
AU2015246141B2 (en) 2016-07-07
JP2016106091A (ja) 2016-06-16
AU2011308856B2 (en) 2015-04-23
PH12013500579A1 (en) 2016-06-10
RU2015150728A (ru) 2019-01-15
PL3040333T3 (pl) 2019-03-29
AU2015200938A1 (en) 2015-03-12
TWI540133B (zh) 2016-07-01
CL2013000850A1 (es) 2013-09-27
CN104987321A (zh) 2015-10-21
US9452994B2 (en) 2016-09-27
RU2576619C2 (ru) 2016-03-10
SI3040333T1 (sl) 2019-01-31
ES2699951T3 (es) 2019-02-13
AU2015200938B2 (en) 2015-11-19
CN103140479B (zh) 2015-04-08
LT3040333T (lt) 2018-12-10
EP2621908A2 (en) 2013-08-07
SG188439A1 (en) 2013-05-31
BR112013007123B1 (pt) 2021-11-09
US9181215B2 (en) 2015-11-10
AU2015200936A1 (en) 2015-03-12
PE20140002A1 (es) 2014-01-21
IL233282A (en) 2016-08-31
EP3040333B1 (en) 2018-09-12
DK3040333T3 (da) 2019-01-02

Similar Documents

Publication Publication Date Title
KR20130119928A (ko) 피리미딘 유도체의 제조 방법
CA2759241C (en) Novel anti-inflammatory agents
EP1575940B1 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
CA2901022A1 (en) Substituted pyridine compounds as inhibitors of histone demethylases
AU2012214413A1 (en) Method of inhibiting hamartoma tumor cells
JP7664642B2 (ja) 化合物およびｍｉｆ阻害剤としての用途
HK1153471B (en) 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130430

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160927

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170821

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180123

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180718

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20170821

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180718

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20171023

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160927

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180827

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180817

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180718

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180123

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171023

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170821

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160927

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181107

PJ0201 Trial against decision of rejection

Patent event date: 20181107

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180827

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20180718

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190910

Appeal identifier: 2018101004557

Request date: 20181107

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101004557; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20181107

Effective date: 20190910

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190910

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20181107

Decision date: 20190910

Appeal identifier: 2018101004557